Use of recombinant factor VIIa to treat persistent bleeding following dental extractions in two cirrhotic patients.
OBJECTIVE
A single dose of recombinant factor VIIa (rFVIIa) has been shown to be effective and safe in correcting the prothrombin time (PT) in cirrhotic patients, but no clinical data exists demonstrating its efficacy in arresting active bleeding.


METHODS
rFVIIa was used in two cirrhotic patients for persistent bleeding following dental extractions despite repeated treatment at the wound site and, in one case, repeated administrations of fresh-frozen plasma (FFP).


RESULTS
Bleeding stopped promptly in both patients after administration of rFVIIa. However, bleeding recurred in the patient who had not received concomitant treatment at the extraction sites. No recurrence of bleeding was observed in the second patient, who underwent local treatment 15 min after rFVIIa.


CONCLUSIONS
Recombinant factor VIIa arrested bleeding after dental extractions in two cirrhotic patients who had been unsuccessfully treated with FFP. However, additional local treatment is needed to limit the risk of recurrence as a result of the short half-life of rFVIIa.
Berthier
A-M
AM
Department of Haematology, University Hospital, Rennes, France. Anne-Marie.Berthier@chu-rennes.fr
Guillygomarc'h
A
A
Messner
M
M
Pommereuil
M
M
Bader
G
G
De Mello
G
G
D000328:Adult; D015942:Factor VIIa / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011517:Prothrombin Time; D011994:Recombinant Proteins; D014081:Tooth Extraction / Q000009:adverse effects*
D011994:Recombinant Proteins; D015942:Factor VIIa